Zylox-Tonbridge Medical Technology Co., Ltd. (HKG:2190)
19.08
-0.01 (-0.05%)
Jul 31, 2026, 4:08 PM HKT
HKG:2190 Ratios and Metrics
Market cap in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 6,323 | 7,792 | 3,767 | 4,075 | 4,268 | 8,476 | |
Market Cap Growth | -20.16% | 106.85% | -7.55% | -4.52% | -49.65% | - |
Enterprise Value | 4,466 | 6,114 | 2,597 | 2,287 | 1,002 | 7,606 |
Last Close Price | 19.08 | 22.82 | 11.57 | 12.22 | 12.61 | 25.05 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 22.70 | 28.66 | 35.31 | - | - | - |
Forward PE | 15.70 | 23.84 | 19.34 | 62.73 | - | - |
PS Ratio | 5.37 | 6.62 | 4.52 | 7.01 | 11.30 | 38.81 |
PB Ratio | 1.76 | 2.17 | 1.14 | 1.21 | 1.22 | 2.20 |
P/TBV Ratio | 1.78 | 2.20 | 1.15 | 1.22 | 1.22 | 2.20 |
P/FCF Ratio | 20.76 | 25.59 | - | - | - | - |
P/OCF Ratio | 14.76 | 18.20 | 20.34 | 37.58 | - | - |
PEG Ratio | 0.26 | 0.40 | - | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.80 | 5.20 | 3.12 | 3.93 | 2.65 | 34.83 |
EV/EBITDA Ratio | 17.03 | 23.69 | 26.84 | - | - | - |
EV/EBIT Ratio | 20.19 | 27.63 | 41.53 | - | - | - |
EV/FCF Ratio | 14.67 | 20.08 | - | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.02 | 0.02 | 0.03 | 0.02 | 0.01 | 0.00 |
Debt / EBITDA Ratio | 0.27 | 0.27 | 0.95 | - | - | - |
Debt / FCF Ratio | 0.23 | 0.23 | - | - | - | - |
Net Debt / Equity Ratio | -0.52 | -0.52 | -0.38 | -0.48 | -0.60 | -0.93 |
Net Debt / EBITDA Ratio | -7.19 | -7.19 | -13.11 | 11.49 | 9.08 | 14.00 |
Net Debt / FCF Ratio | -6.10 | -6.10 | 69.05 | 15.73 | 8.17 | 15.02 |
Asset Turnover | 0.30 | 0.30 | 0.23 | 0.16 | 0.10 | 0.10 |
Inventory Turnover | 1.44 | 1.44 | 1.09 | 0.82 | 0.67 | 0.76 |
Quick Ratio | 5.38 | 5.38 | 3.89 | 4.80 | 12.32 | 30.22 |
Current Ratio | 5.98 | 5.98 | 4.58 | 5.40 | 13.56 | 31.14 |
Return on Equity (ROE) | 7.72% | 7.72% | 3.26% | -2.56% | -3.64% | -11.19% |
Return on Assets (ROA) | 3.54% | 3.54% | 1.08% | -2.93% | -4.30% | -7.27% |
Return on Capital Employed (ROCE) | 6.10% | 6.10% | 1.90% | -5.10% | -7.20% | -6.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 4.30% | 3.49% | 2.83% | -2.13% | -3.01% | -2.89% |
FCF Yield | 4.82% | 3.91% | -0.49% | -2.50% | -5.99% | -2.81% |
Dividend Yield | 1.34% | 1.07% | 0.92% | - | - | - |
Payout Ratio | 13.38% | 13.38% | - | - | - | - |
Buyback Yield / Dilution | 1.34% | 1.34% | 0.22% | 0.51% | -12.15% | -51.26% |
Total Shareholder Return | 2.67% | 2.41% | 1.14% | 0.51% | -12.15% | -51.26% |